OUR MISSION
To be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
CHIEF TECHNOLOGY OFFICER
Prof. Matthew J Baker
Inventor with 18+ years’ experience in the field of clinical spectroscopy. Top 6 KPMG Best British Tech Pioneers (2020), Fellowship of the Society for Applied Spectroscopy (2020), Top 40 under 40 Analytical Scientists (2018), RSC Harrison Meldola Prize (2017) and Emerging Leader in Molecular Spectroscopy (2016). Professor of Early Diagnostics, School of Medicine, University of Central Lancashire.
CHIEF EXECUTIVE OFFICER
Dr Mark Hegarty
20+ years' experience in startups and healthcare products, successfully building international B2B sales and relationships across 20+ countries.
Previously led Daysoft Limited from zero to £10m sales per annum, realizing an initial £3m return to investors and creating 220 jobs. Formerly was Operations Manager of Scherer Drug Delivery Systems which was acquired by Cardinal Health and is now a Catalent company.
FINANCE DIRECTOR
John Duncan
A Chartered Accountant with 15+ years' experience gained in business financing through private equity and VC investments.
HEAD OF DEVELOPMENT
Dr Holly J Butler
11+ years' experience in the clinical spectroscopy field. 'Young Entrepreneur' of the year winner, 2017 – Scottish Women's Awards 'Women in Innovation' winner, 2017 – Global Game Changers Awards. Experienced researcher in biophotonics and infrared analysis.
OPERATIONS DIRECTOR
Dr David Eustace
13+ years' experience in regulated diagnostic product development and medical device production in both start-up and multinational environments, most recently as Operations Director at Bruker Daltonics Microbiology and Diagnostics Division.
CHIEF DATA SCIENTIST
Dr David S Palmer
18+ years' experience in the field of data analysis and machine learning. Computational chemist, leading the design and development of the Dxcover diagnostic algorithms. Reader in Chemistry at the University of Strathclyde.
THE BOARD
NON-EXECUTIVE CHAIRMAN
Professor Steven Howell
Highly experienced Chair and serial entrepreneur, having commercialized 10 products in diagnostics and healthcare. Formerly held senior positions in Alere and Inverness Medical.
INVESTOR DIRECTOR
Dr Andrew McNeill
Andrew McNeill is Managing Partner at Eos Advisory. He has over 15 years’ experience in leading early-stage venture capital backed medical device and biotech companies.
NON-EXECUTIVE DIAGNOSTICS
Dr Stephen Little
Strong track record as a diagnostics leader. Former Founder & CEO of DxS (sold to Qiagen for $130M), former R&D Manager Astra Zeneca Diagnostics, and current Vice Chairman at Yourgene Health.
INVESTOR DIRECTOR
Professor David Onions
Representing Norcliffe Capital Limited, Prof Onions has extensive experience in growing and commercializing businesses in the Life Sciences and Biotech sector.
SCIENTIFIC ADVISORY BOARD
READER & HONORARY CONSULTANT NEUROSURGEON
Dr Paul Brennan, MB BChir PhD FRSC (SN)
Reader and Consultant Neurosurgeon at the University of Edinburgh and NHS Lothian. Strong track record leading clinical trials and laboratory research, with major focus on brain tumors. Experience as med-tech medical advisor, and founder of university spin-out eoSurgical Ltd providing surgical simulation training around the world.